Home・Lista de Ações・Editas Medicine Inc

Editas Medicine Inc

Fechado

SetorSaúde

2.83 0.35

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.7800000000000002

Máximo

2.89

Indicadores-chave
By Trading Economics
Rendimento	6.8M -18M
Vendas	9.1M 12M
EPS	-0.15
Margem de lucro	-153.322
Funcionários	87
EBITDA	3.9M -20M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+183.69% upside

Dividendos
By Acuity
Próximos Ganhos	9 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	25M 432M
Abertura anterior	2.48
Fecho anterior	2.83

Sentimento de Notícias

By Acuity

75%

25%

302 / 340 Ranking em Healthcare

Editas Medicine Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de ago. de 2026, 22:21 UTC

Editas Medicine Inc is trading lower in after-market hours, continuing a decline over the past four sessions amid broader concerns over consumer demand.

13 de ago. de 2026, 21:32 UTC

Correlated Moves

Editas Medicine Inc advanced in after-hours trading, reflecting a shift in investor sentiment and aligning with a positive trend in the biotechnology sector.

12 de ago. de 2026, 19:31 UTC

Editas Medicine Inc shares are lower today, continuing a decline since Tuesday. No specific news has been identified to explain the drop.

11 de ago. de 2026, 19:46 UTC

Editas Medicine Inc shares are trading higher today, reflecting unusual strength. No specific company news was identified to explain this price action.

10 de ago. de 2026, 23:26 UTC

Editas Medicine Inc shares are higher in after-market hours. No specific company news was identified to explain this movement amid broader market uncertainties.

7 de ago. de 2026, 23:16 UTC

Editas Medicine Inc. shares were little changed in after-market trading, with no specific news identified. The stock remains above its 20-day moving average.

6 de ago. de 2026, 23:02 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum following a strong trading session despite no specific company news.

5 de ago. de 2026, 22:02 UTC

News

Editas Medicine reports second-quarter loss of $18.2 million, better than expected. Shares are higher after positive updates on EDIT-401 program and revenue growth.

31 de jul. de 2026, 19:56 UTC

Correlated Moves

EDIT shares lower amid broader biotech sector decline today.

30 de jul. de 2026, 23:51 UTC

Editas Medicine Inc shares are lower in after-market trading, continuing a decline since Thursday's close while remaining near the lower end of its one-month range.

29 de jul. de 2026, 23:46 UTC

Editas Medicine Inc shares are lower in after-market hours, with no specific news identified. The stock remains near its one-month low amid broader market caution.

28 de jul. de 2026, 20:07 UTC

Editas Medicine Inc shares are trading lower today, continuing a broader trend in the biotechnology sector. The stock remains below its 20-day moving average.

27 de jul. de 2026, 17:26 UTC

Editas Medicine Inc is trading higher today, following a notable peak. The upward movement comes amid easing inflation concerns from declining oil prices.

24 de jul. de 2026, 17:46 UTC

Editas Medicine Inc shares are lower today, continuing a trend of declines over the past three sessions amid broader market volatility linked to falling oil prices.

22 de jul. de 2026, 19:26 UTC

Editas Medicine Inc is lower today, continuing a decline since Tuesday's close. Broader market weakness may be influencing investor sentiment.

21 de jul. de 2026, 23:11 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum since Tuesday's close, though they remain below their 20-day moving average.

Comparação entre Pares

Variação de preço

Editas Medicine Inc Previsão

Preço-alvo

By TipRanks

183.69% parte superior

Previsão para 12 meses

Média 8 USD 183.69%

Máximo 15 USD

Mínimo 4 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Editas Medicine Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

Comprar

Manter

Vender

Com base em 6 analistas que deram avaliações de ações para Editas Medicine Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

302 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.